Jefferies analyst Eun Yang assumes Aerovate Therapeutics (NASDAQ:AVTE) with a Buy rating and raises Price Target to $65.
Jefferies Assumes Aerovate Therapeutics at Buy, Raises Price Target to $65
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.